Literature DB >> 21905151

The role of private medical insurance in socio-economic inequalities in cancer screening uptake in Ireland.

Brendan Walsh1, Mary Silles, Ciaran O'Neill.   

Abstract

Screening is seen by many as a key element in cancer control strategies. Differences in uptake of screening related to socio-economic status exist and may contribute to differences in morbidity and mortality across socio-economic groups. Although a number of factors are likely to underlie differential uptake, differential access to subsequent diagnostic tests and/or treatment may have a pivotal role. This study examines differences in the uptake of cancer screening in Ireland related to socio-economic status. Data were extracted from SLÁN 2007 concerning uptake of breast, cervical, colorectal and prostate cancer screening in the preceding 12 months. Concentration indices were calculated and decomposed. Particular emphasis was placed in the decomposition upon the impact of private health insurance, evidenced in other work to impact on access to care within the mixed public-private Irish health system. This study found that significant differences related to socio-economic status exist with respect to uptake of cancer screening and that the main determinant of difference for breast, colorectal and prostate cancer screening was possession of private insurance. This may have profound implications for the design of cancer control strategies in countries where private insurance has a significant role, even where screening services are publicly funded and population based.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21905151     DOI: 10.1002/hec.1784

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  8 in total

1.  Trends and Determinants in Uptake of Cervical Cancer Screening in Spain: An Analysis of National Surveys from 2017 and 2020.

Authors:  Silvia Portero de la Cruz; Jesús Cebrino
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

2.  Socio-economic inequalities in the multiple dimensions of access to healthcare: the case of South Africa.

Authors:  Tanja Gordon; Frederik Booysen; Josue Mbonigaba
Journal:  BMC Public Health       Date:  2020-03-04       Impact factor: 3.295

3.  Parental education is associated with differential engagement of neural pathways during inhibitory control.

Authors:  Christopher N Cascio; Nina Lauharatanahirun; Gwendolyn M Lawson; Martha J Farah; Emily B Falk
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.996

4.  Study on Equity and Efficiency of Health Resources and Services Based on Key Indicators in China.

Authors:  Xinyu Zhang; Lin Zhao; Zhuang Cui; Yaogang Wang
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

5.  The role of private care in the interval between diagnosis and treatment of breast cancer in Northern Ireland: an analysis of Registry data.

Authors:  Patricia Carney; Anna Gavin; Ciaran O'Neill
Journal:  BMJ Open       Date:  2013-12-03       Impact factor: 2.692

6.  Factors driving inequality in prostate cancer survival: a population based study.

Authors:  Richéal M Burns; Linda Sharp; Francis J Sullivan; Sandra E Deady; Frances J Drummond; Ciaran O Neill
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

7.  Challenges in generating costs and utilisation rates associated with castration-resistant prostate cancer.

Authors:  Siobhan Bourke; Richéal Maria Burns; Caroline Gaynor
Journal:  J Mark Access Health Policy       Date:  2014-07-04

8.  Cancer cases detected in the prevention and control service of a private cancer clinic in Peru.

Authors:  José Revilla-López; Andrea Anampa-Guzmán; Luis Casanova Marquez; Katrina Weeks; Suzanne Pollard; Adriel Olórtegui-Yzú; María Ruiz-Velazco; Alba Davila-Edquen; Daniel Castro-Dorer; Juan Wong-Barrenechea; Jossira Abad-Seminario; Pamela Gonzáles-Ramos; Fiorella Rivera-Sandoval; Carlos Carracedo-Gonzáles
Journal:  Infect Agent Cancer       Date:  2019-11-29       Impact factor: 2.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.